Drug Profile
Research programme: antibacterials - BioPort/University of Maryland
Latest Information Update: 30 Apr 2007
Price :
$50
*
At a glance
- Originator University of Maryland, College Park
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 16 Jun 2003 The assets of Antex Biologics and Antex Pharma have been acquired by BioPort Corporation
- 06 Dec 2002 This programme is still in active development
- 06 Nov 2000 Preclinical development for Bacterial infections in USA (Unknown route)